Keep up with IRX Therapeutics

News & Events

IRX Therapeutics to Present at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference

NEW YORK – April 3, 2017 – IRX Therapeutics, Inc. (IRX) today announced that Mark Leuchtenberger, the Company’s President and Chief Executive Officer, will present a corporate overview at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference on Friday, April 7, 2017, at 3:00 p.m. Eastern time. The conference will be held at the Millennium Broadway Hotel & Conference Center in New York City.

About IRX Therapeutics

IRX Therapeutics is a clinical-stage company developing novel immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor micro-environment, restoring immune function, and activating a coordinated immune response against the tumor. The lead candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine components. Data collected to date indicates that IRX-2 acts to restore and activate multiple immune cell types, including T cells, dendritic cells, and natural killer cells, to recognize and destroy tumors. For more information about the Company and its clinical programs, please visit www.IRXTherapeutics.com.

Media Inquiries

MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com